Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. School of Medicine / 醫學系
  4. Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma
 
  • Details

Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma

Journal
Oncology reviews
Journal Volume
13
Journal Issue
1
Pages
15-22
Date Issued
2019
Author(s)
SHANG-YI HUANG  
Chen T.-Y.
Kuo C.-Y.
Chen Y.-C.
Lin S.-F.
Chang M.-C.
Lv X.
Yang B.
Chang C.-S.
DOI
10.4081/oncol.2019.377
URI
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060199238&doi=10.4081%2foncol.2019.377&partnerID=40&md5=57bac565e151b0c3b8cafa63c05adda3
https://scholars.lib.ntu.edu.tw/handle/123456789/540529
Abstract
Bortezomib is a proteasome inhibitor, approved for treating newly diagnosed and relapsed multiple myeloma (MM). This real-world, multicenter, observational, non-interventional study of bortezomib was designed to collect and analyze prospective data in Taiwanese patients with relapsed or refractory MM. The primary endpoints included clinical effectiveness outcomes (disease response, disease progression [PD], time-to-response, time-to-progression, response duration, and overall survival [OS]). Secondary endpoints were safety and healthcare resource utilization. Total 100 patients (median [range] age 64.9 [37.0-85.5] years) were enrolled; 47 patients completed the study. Of the withdrawn patients (n=53), there were 48 deaths (PD-related death: n=35, adverse events [AEs]-related: n=12, other reason: n=1), and 5 due to loss to follow-up. Four patients in Cycle 1, 6 patients each in Cycle 2 and 5, 7 in Cycle 3, 10 patients in Cycle 4, 5 patients in Cycle 6, and 3 patients each in Cycle 7 and 8 achieved overall response during the study. Time-to-response was 4.68 months (95%CI: 3.2, NE) and response duration was 10.08 months (95%CI: 2.3, 28.6). Median OS was 9.8 months (95%CI: 3.8, 13.7), and median time-to-progression was 11.3 months (95%CI: 6.2, 20.2). Most common non-hematological AEs were diarrhea (n=32) and hypoesthesia (n=25); most common hematological AE was thrombocytopenia (n=18). Efficacy and safety profile of bortezomib in Taiwanese patients with MM was similar to global and other Asian population. Study provides a critical insight on use of bortezomib in real-world clinical practice, which can be helpful for Taiwanese healthcare providers’ decision-making processes. ?Copyright S-Y. Huang et al., 2019.
Subjects
Bortezomib; Effectiveness; Multiple myeloma; Observational; Real-world
SDGs

[SDGs]SDG3

Other Subjects
bortezomib; lactate dehydrogenase; M protein; abdominal distension; abdominal pain; acute heart infarction; acute respiratory failure; adult; adult respiratory distress syndrome; aged; backache; basophil; bone lesion; clinical practice; constipation; coughing; decreased appetite; diarrhea; dizziness; drug dose reduction; drug efficacy; drug safety; drug withdrawal; eosinophil; erythrocyte count; fatigue; female; fever; follow up; health care utilization; hematocrit; hemoglobin blood level; herpes zoster; human; hypesthesia; hypokalemia; insomnia; lacunar stroke; lymphocyte; major clinical study; malaise; male; median survival time; medication compliance; monocyte; multicenter study; multiple cycle treatment; multiple myeloma; neutrophil; observational study; patient compliance; peripheral edema; peripheral neuropathy; plasmacytoma; platelet count; pneumonia; post treatment survival; priority journal; rash; respiratory failure; Review; rhinorrhea; sepsis; septic shock; spinal cord compression; Taiwanese; thrombocytopenia; treatment duration; treatment response time; upper respiratory tract infection; vomiting
Publisher
Page Press Publications
Type
review

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science